Research At a Glance
- Research Category
- Growth Hormone Axis Research
- Peptide Length
- 44 amino acids (GHRH analogue)
- Purity
- ≥ 98% (HPLC)
- Published Studies
- ~120 indexed
- Storage
- Lyophilized: −20 °C long term, 2–8 °C short term. Reconstituted: 2–8 °C, use within 30 days.
Published-study figures are approximate PubMed result counts and indicate the volume of available literature only. Purity reflects third-party analytical testing on the corresponding lot; see the Quality Assurance Center for lot-matched certificates.
What Is Tesamorelin?
Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH 1-44), engineered with an N-terminal modification that protects it from enzymatic cleavage by DPP-4, giving it enhanced stability compared to native GHRH in research models. Tesamorelin is studied as a GHRH receptor agonist that stimulates endogenous growth hormone secretion at the pituitary level, distinguishing its research mechanism from direct GH administration.
Note: Tesamorelin has received regulatory approval in some jurisdictions under a specific prescription brand name for a defined clinical indication. Queen BioLabs supplies this compound strictly for laboratory and analytical research purposes; it is not sold, marketed, or intended for human or veterinary use, consumption, or administration in any form.
Why Researchers Study It
- GHRH receptor pathway research — tesamorelin is studied for its upstream activation of the GHRH receptor on pituitary somatotroph cells, prompting endogenous GH synthesis and release rather than direct hormone administration
- Visceral adipose tissue research — the compound has an unusually deep published clinical research base examining reductions in visceral fat, most extensively studied via CT-imaging endpoints in controlled trial research
- Hepatic lipid research — research has extended into liver fat content and non-alcoholic fatty liver disease (NAFLD) research models, motivated by the GH axis's established role in hepatic lipid handling
- Cognitive and GH/IGF-1 axis research — a smaller research line has examined tesamorelin's relationship to cognitive function outcomes in older adult research populations, grounded in the GH/IGF-1 axis's role in brain physiology
What the Published Literature Shows
Tesamorelin has one of the more extensive published clinical research bases among GHRH-class research compounds, including multiple randomized controlled trials rather than preclinical work alone. A meta-analysis of randomized controlled trials evaluating tesamorelin against placebo found statistically significant reductions in visceral adipose tissue and trunk fat measures across the pooled trial data, along with associated changes in metabolic and hormonal markers. Separate clinical research has examined tesamorelin's effects on liver fat content, with trial data indicating reductions in liver fat and prevention of inflammation and fibrosis progression in specific research populations.
Researchers studying the GHRH analog class have noted tesamorelin's mechanistic distinction from ghrelin-receptor-acting secretagogues (such as ipamorelin), given that its GHRH-receptor mechanism has been associated in research models with more physiological GH release patterns relative to compounds that also stimulate cortisol and prolactin release.
Source
Falutz J, et al. Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Associated Lipodystrophy. N Engl J Med. 2007. Additional literature via PubMed — tesamorelin GHRH research .
Compound Specifications
| Classification | Synthetic GHRH (1-44) analog |
|---|---|
| Molecular target | GHRH receptor |
| Format | Lyophilized powder |
| Purity | ≥99% (HPLC-verified per lot) |
| Storage | −20°C; refrigerate 2–8°C after laboratory handling |
Certificate of Analysis
Every lot is independently tested and lot-matched. View Certificates of Analysis